文章摘要
张小玲,宋徽,肖云,高晓唯,张燕.玻璃体腔注射康柏西普治疗葡萄膜炎继发黄斑水肿疗效观察[J].中国医药导刊,2017,19(12):1356-1360.
玻璃体腔注射康柏西普治疗葡萄膜炎继发黄斑水肿疗效观察
Observation of Therapeutic Effect of Intravitreal Injection of Conbercept for Uveitic Cystoid Macular Edema
投稿时间:2017-09-21  修订日期:2017-09-21
DOI:
中文关键词: 康柏西普  葡萄膜炎黄斑水肿  玻璃体腔注射
英文关键词: Conbercept  Uveitic cystoid macular edema  Intravitreal injection
基金项目:
作者单位E-mail
张小玲 解放军第474医院 13901389084@139.com 
宋徽 解放军第309医院  
肖云 解放军第474医院眼科  
高晓唯 解放军第474医院  
张燕 解放军第474医院  
摘要点击次数: 365
全文下载次数: 222
中文摘要:
      目的:评估玻璃体腔注射康柏西普治疗葡萄膜炎继发黄斑水肿的临床疗效。方法:选取2013年7月至2015年9月我院门诊收治的24例33眼葡萄膜炎继发黄斑水肿患者作为研究对象,依据治疗方法分为两组:玻璃体腔注射康柏西普治疗组(康柏西普组,n=12,17眼)和玻璃体腔注射曲安奈德治疗组(曲安奈德组,n=12,16眼)。采用最佳矫正视力(BCVA)、荧光素眼底血管造影术(FFA)、光学相干断层扫描技术/光学相干层析成像(OCT)及中央视网膜厚度(CRT)评估治疗6个月后药物临床疗效。结果:治疗前两组患者BCVA、OCT之间的差异均无统计学意义(P>0.05),治疗后6个月与曲安奈德组相比,康柏西普组患者的BCVA显著较高,差异有统计学意义(P<0.05),OCT显著较低,差异有统计学意义(P<0.05);和治疗前相比,治疗后6个月两组患者BCVA显著较高,差异有统计学意义(P<0.05),OCT显著较低,差异有统计学意义(P<0.05)。FFA检查:治疗的24例33眼中,均未发现新的出血部位,也没有新的血管形成;其中13例患者19只患眼黄斑部渗漏病变,相较治疗前范围减小,另外11例14眼黄斑部已观察不到病变。康柏西普组患者治疗的总有效率94.1%(16/17)显著高于曲安奈德组75.0%(12/16),差异有统计学意义(P<0.05)。曲安奈德组并发症发生率为35.3%,康柏西普组并发症发生率为25.0%,两组患者并发症发生率之间的差异无统计学意义(P>0.05)。结论:玻璃体腔注射康柏西普能有效治疗葡萄膜炎继发黄斑水肿,治疗后患者视力稳定。
英文摘要:
      Objective:To determine the therapeutic effect of intravitreal injection of conbercept ophthalmic injection (conbercept) for the treatment of uveitic cystoid macular edema.Methods:24 patients of 33 eyes with uveitic cystoid macular edema treated by intravitreal injection of conbercept during July 2013 to September 2015 were divided into two groups: intravitreal injection of conbercept ophthalmic injection treatment group (conbercept,n=12,17 eyes) and intravitreal injection of triamcinolone acetonide injection treatment group (triamcinolone acetonide group,n=12,16 eyes)according to the treatment methods.The best corrected visual acuity(BCVA),fluorescein fundusangiography(FFA),optical coherence tomography(OCT)and central retinal thickness(CRT)were observed on the therapeutic effect of drug after 6 months.Results:Before treatment,the differences of BCVA and OCT between the two groups of patients were not statistical significant(P>0.05). Compared with the triamcinolone acetonide group,the BCVA of the conbercept group after 6 months treatment was significantly higher, there was statistical significance(P<0.05),the OCT was significantly lower, there was statistical significance(P<0.05).Compared with before treatment,the BCVA after 6 months treatment of the two groups of patients was significantly higher, there was statistical significance(P<0.05),the OCT was significantly lower, there was statistical significance (P<0.05).FFA examination: no new bleeding site were found in 33 eyes of 24 cases, and no new blood vessels were formed.Of them,13 cases of patients had 19 eyes with macular leakage. Compared with before treatment,the range of them decreased,and 11 cases of 14 eyes were not observed in macular.The total effective rate 94.1% (16/17) of the compaitcept group was significantly higher than the triamcinolone acetonide group 75.0% (12/16), there was statistical significance (P<0.05).The incidence of complication rate of triamcinolone acetonide group was 35.3%, the incidence of complication of the conbercept group was 25.0%, the difference between two groups was not statistical significant(P>0.05).Conclusion:Intravitreal injection of conbercept can be effective in the treatment of uveitic cystoid macular edema and patients with stable vision after injection.
查看全文   查看/发表评论  下载PDF阅读器